Cerebrolysin
Research OnlyAlso known as: FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Research Statistics
Approved in Eastern Europe and Asia; RCTs exist in multiple countries but Western adoption limited.
Research Dossier
Overview
What is Cerebrolysin and what does the research say?
Mechanism of Action
Cerebrolysin is a complex mixture of porcine brain-derived peptide fragments and free amino acids. Its proposed mechanisms are supported by both preclinical studies and multiple Phase 3 clinical trials, though the exact active components remain to be fully characterized.
How It Works (Simplified)
Cerebrolysin contains small protein fragments that mimic natural brain growth factors (neurotrophins), providing multimodal neuroprotective and neurorestorative support:
Peptide fragments mimic BDNF, NGF, GDNF, and CNTF, activating TrkB and TrkA receptors to promote neuronal survival and synaptic plasticity.
Activates sonic hedgehog pathway, stimulating neural progenitor proliferation in hippocampus and promoting new neuron formation.
Protects neurons from glutamate excitotoxicity, ischemia, and oxidative stress through PI3K/Akt survival pathway activation.
Promotes oligodendrocyte function and white matter repair, supporting recovery of neural connectivity after stroke or injury.
Scientific Pathways
Neurotrophic Factor Mimicry (Neuronal Survival)
Cerebrolysin peptides → TrkB/TrkA-like activation → PI3K → Akt → Neuronal survival
↓
Synaptic plasticity & LTPSonic Hedgehog Pathway (Neurogenesis/Repair)
Cerebrolysin → Sonic hedgehog induction → Neural progenitor proliferation
↓
Neurogenesis + Oligodendrogenesis + AngiogenesisKey Research: CARS trial (Muresanu DF et al. 2016) demonstrated significant motor recovery with NNT=5 in stroke patients. PMID:26564101. Alzheimer’s meta-analysis (Gauthier S et al. 2015) showed OR 3.32 for clinical improvement across 6 RCTs. PMID:25792495
Important Limitations
- Largest stroke trial (CASTA, N=1070) failed primary endpoint - benefit only in severe subgroup [PMID:22246687]
- Cochrane reviews conclude “no convincing evidence” for mortality/dependence reduction in stroke
- Complex mixture composition makes identifying active components difficult
- Not FDA-approved despite 50+ country approvals - no NDA filed
- Most trials manufacturer-sponsored (EVER Neuro Pharma)
- Russian and Chinese primary literature not fully accessible in English
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on clinical trials: Initial neurotrophic signaling begins. IV administration protocols typically show early improvements in cognitive assessments. Most trials use 10-30mL daily IV infusion.
CARS stroke trial showed significant motor improvements emerging by 3-4 weeks. Cognitive improvements in dementia trials become measurable. Sonic hedgehog pathway activation promotes ongoing neurogenesis.
Sustained neuroplasticity effects. Alzheimer's trials showed continued ADAS-cog improvement through treatment period. Motor recovery in stroke continues to progress.
Effects persist 3 months post-treatment in Alzheimer's studies. Long-term follow-up suggests disease-modifying potential. Treatment courses of 4-8 weeks are common in clinical practice.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Cerebrolysin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Cerebrolysin with other peptides. Based on published research and mechanistic considerations.
Cortexin
SynergisticBoth are brain-derived peptide preparations used in Russian neurology for similar indications. May have additive neuroprotective effects.
Semax
CompatibleBoth are neuroprotective peptides used in Russian clinical practice. Semax targets BDNF/NGF pathways similar to cerebrolysin's neurotrophic mechanisms. No known contraindications.
Selank
CompatibleSelank's anxiolytic and immunomodulatory effects complement cerebrolysin's neuroprotective actions. Both used in Russian neurological practice.
BPC-157
CompatibleBPC-157's systemic cytoprotective effects may complement cerebrolysin's CNS-specific neuroprotection. Different target tissues with no known interactions.
Dihexa
CompatibleBoth promote neuroplasticity through different mechanisms - cerebrolysin via neurotrophic factors, Dihexa via HGF/c-Met pathway. Theoretical complementary effects.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Cerebrolysin
Cerebrolysin Calculators
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank, N-Acetyl Selank, Acetyl-Selank-Amidate +1 more
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.